麦肯锡 -2027 年及以后美国医疗行业展望 What to expect in US healthcare in 2027 and beyond_第1页
麦肯锡 -2027 年及以后美国医疗行业展望 What to expect in US healthcare in 2027 and beyond_第2页
麦肯锡 -2027 年及以后美国医疗行业展望 What to expect in US healthcare in 2027 and beyond_第3页
麦肯锡 -2027 年及以后美国医疗行业展望 What to expect in US healthcare in 2027 and beyond_第4页
麦肯锡 -2027 年及以后美国医疗行业展望 What to expect in US healthcare in 2027 and beyond_第5页
已阅读5页,还剩33页未读, 继续免费阅读

下载本文档

版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领

文档简介

McKinsey

&Company

HealthcarePractice

Whattoexpectin

UShealthcarein2027andbeyond

Theeconomicpressureonthehealthcaresystemisrelentless.Valuewillaccruetoorganizationsthatcanturnfinancialpressureintoincreasedproductivityandbetterpatientoutcomes.

byNehaPatelandShubhamSinghal

withAnkitJain

November2026

ThestormcontinuestopassthroughtheUShealthcaresystem.Thepressuresidentifiedinourseries

of"gatheringstorm"articles¹firstbecamevisibleinprovidereconomicsandhavesincemovedintopayer

marginsandpatientaffordability.AccordingtoMcKinseyanalysis,providerEBITDAfellto$241billionin

2022beforerecoveringto$350billionin2025,whilepayerEBITDAfellfrom$60billionin2022to$9billionin2025.Thisisnotauniformcycle:Asonesegmentrebounds,pressureisoftentransmittedtoanother

throughreimbursement,pricing,utilization,orcoverage.

Theforcessustainingthatpressurearestructural.The2026USfederaldeficitisforecastat$1.9tillion,or5.8percentofGDP,andUSdebthascrossed$40trillion,constrainingfiscalflexibilityevenashealthcarespendingrises.3Healthcaredeliveryproductivitydeclinedabout1percentannuallyfrom2019to2025,

comparedwith2percentgrowthinthebroaderprivateeconomy.Meanwhile,nationalhealthexpenditures(NHE)percapitaroseroughly3.5timesfrom2000to2025,yethealthylifeexpectancyimprovedbyonlyeightmonths.5Thesystemisspendingsubstantiallymorewithoutacommensurateincreaseinhealthylife.

Industryeconomicsarelikelytoremaindepressedrelativetotheirprepandemiclevel.EBITDArepresented10.9percentofNHEin2019comparedwith9.6percentin2025.WeprojectnominalEBITDAgrowthinthecomingyears,butthatshouldnotbemistakenforarestorationofhistoricaleconomics.

Theoutlookinthisreportassumesmaterialmanagementaction.Forproviders,marginscouldpotentiallyincreaseby50basispointsofincrementalreimbursementfrompayersandbyupto100basispoints

fromproductivitygainsandtechnology-enabledoperatingredesign.Forpayers,portfolioshifts,productoptimization,andselectiveexitscouldcontributeupto200basispointsofmarginimprovement.Forbothprovidersandpayers,thesewouldbesizablenetimprovementsdespitecontinuingchallenges.Butwithoutmanagementaction,theunderlyingtrajectoryshowninourprojectionswouldbeweaker.

Valuewillcontinuetomigratetowardbusinessmodelsthatenablecaredeliveryinlower-costsettingsor

operatethesystemmoreefficiently.Ambulatorysurgerycenter(ASC)EBITDAisprojectedtogrow6.7

percentannuallyfrom2025to2030versus3.7percentforhospitals.Duringthesameperiod,specialty

pharmacydrugspendingisprojectedtogrow9.6percentannuallyversus7.0percentfortraditionaldrugspending,⁶whileapplicationsofAlareexpectedtoshifttowardsoftware,platforms,data,andtechnology-enabledservices.UShealthcareisnotreturningtoitsoldequilibrium;valuewillaccruetotheorganizationsthatfindwaystoturnfinancialpressureintoincreasedproductivityandbetterpatientoutcomes.

Severalhealthcaresegmentsareexpectedtofacefinancialpressure

WeestimatethatoverallhealthcareEBITDA⁷willgrow7percentannuallyfrom2025to2030(Exhibit1).

Butthetrajectorywillbeuneven.EBITDAgrowthisexpectedtoslowto4percentannuallythrough2027asdisenrollmentfromAffordableCareAct(ACA)policiesandMedicaidpolicychangesweighonpayerandprovidereconomicsbeforeacceleratingto9percentannuallyfrom2027to2030.Healthcareservicesandtechnology(HST)andpharmacyservicesshouldseerelativelysteadygrowththroughtheperiod.Providergrowthisweightedtowardthelatterhalfofthedecade,whilepayerEBITDAisprojectedtorecoverfromadepressed2025base.

1"ThegatheringstorminUShealthcare,"McKinsey,accessedOctober10,2026.

2ThefindingscitedinthisarticlearebasedonMcKinsey'sannuallyupdatedhealthcarevaluepoolmodel.

3Thebudgetandeconomicoutlook:2026to2036,CongressionalBudgetOffice,updatedMarch24,2026.

4"Privatecommunityhospitalslaborproductivity"USBureauofLaborStatistics,August26,2026;"TableA.Productivity,output,andinputsintheprivatenonfarmbusinessandprivatebusinesssectorsforselectedperiods,1987-2025,"USBureauofLaborStatistics,updatedMarch19,2026.

5"Nationalhealthexpendituredata,"CMS.gov,updatedSeptember22,2025;"Health,UnitedStates,"CDC,updatedFebruary27,2025.6AdamJ.Fein,2026economicreportonU.S.pharmaciesandpharmacybenefitmanagers,DrugChannelsInstituteteam,March2026.

7Inthisarticle,weuseEBITDAasameasureofeconomichealthoftheindustry.OnlyafractionofEBITDAtranslatesintonetincomefor

theindustry,withnetincomemarginsinthelowsingledigitsafteraccountingforinterest,taxes,depreciation,andamortization.EBITDA

retumsenableorganizationstogeneratethecapitalnecessaryforinvestments,includingthoseforenhancingcapacityandaccess,buildingcapabilitiestooffernewandimprovedtreatmentsandpatientexperience,andfacilitatingtechnology-driventransformation.

WhattoexpectinUShealthcarein2027andbeyond2

Exhibit1

Mostsegmentsarelikelytogrowmorethan5percentperannumby2030.

DistributionofprojectedhealthcareEBITDAacrosshealthcaresegments,2030,$billion

2025-30CAGR,%<00-5-10>10

Individual¹一

Medicaid—

Medicare²—

Coreadminservices

Group

Hospitals

Logistics

andsupply

chain

PBMs

and

PBAs⁸

Phemaand

biotech

Paymertservices

Specialtypharmacy

nd

irfiusionservices

Crical

Services

Broker

solutions

Consutinq

nonacute

Duals

Data

analytics

Office-basedprysicians

Sofware

ad

platformB

Virtualhealthcare

Otherprofessionals

Medicalproducs

Distributors

Diagnostic

Postacute

Ancillary

Traditional

dispensers⁵

HBS

Payers

85

Providers

438

ServicesPharmacyandtechservices

123138

Manufacturers

357

Includesindividualcoveragehealthreimbursementarrangements.2lncludesMedicarePartC,Medicaresupplementinsurance,andMedicarePartD.

Fixed-benefitandsupplemental.Pharmacybenefitmanagersandadministrators(nondispensingsourcesofvaluel.5includeretailandmailpharmacies.Source:McKinseyValuePoolsModel

McKinsey&Company

WhattoexpectinUShealthcarein2027andbeyond3

WhattoexpectinUShealthcarein2027andbeyond4

Payers

Payerprofitabilityhasundergoneahistoricreset.TotalEBITDAfellfromabout$62billionin2023to

$33billionin2024andto$9billionin2025asgrowthinmedicalcostsoutpacedpremiumpricingand

governmentrateupdates.Theyear2025wasthetrough;majorrisk-bearingsegmentscollectivelyturnedunprofitableforthefirsttimethisdecade.EBITDAcouldincreasetoabout$84.5billionby2030,althoughtherecoverywillbeuneven.

Thedeteriorationreflectshigherutilization,risingproviderunitcosts,GLP-1andspecialtypharmacygrowth,andbehavioralhealthdemand,compoundedbyadverseshiftsinriskpoolsacrossMedicaidandtheACA

andbyhigher-than-anticipatedout-of-networkpaymentawardsundertheNoSurprisesAct'sindependentdisputeresolutionprocess.8Theyear2026marksaninflectionpointaspayerpricingbeginstocatchup

withmedical-costtrends,supportedbysubstantialgroupandACApremiumincreasesandcontinued

benefitandproductoptimization.MoremeaningfulEBITDAimprovementshouldemergein2028astheseactionsflowthrough.

Weexpectthegroupcommercialsegmenttoleadtherecovery,supportedbyimprovingfullyinsured

underwritingandcontinuedgrowthinhigher-marginadministrative-services-only(ASO)andstop-loss

businesses.TheMedicareAdvantage(MA)segmentshouldalsograduallyrecoverfrom2025losses,

althoughmarginsmayremainbelowhistoricallevels.Incontrast,ACAandMedicaidsegmentsfacethe

greatestdisruptionsinenrollmentandriskpools,drivenbysubsidyexpirationforACAandeligibilitychangesforMedicaid.

Overall,thesubsector'srecoverywilldependonpricingdiscipline,businessmix,scale,andmedical-cost

management,withdiversifiedearningsstreamsprovidinggreaterresilienceasindustryprofitabilityrebuildsthrough2030.Atthesametime,priceincreasesruntheriskoffurtherenrollmentdecline,particularlyinthesmallgroupcategory.

Providers

ProviderEBITDAcontinuedtorecoverfromalowof$241billionin2022to$322billionin2024and$369billionin2025aspatientvolumesnormalized,reimbursementratesimproved,andlaborandinflationarypressuresmoderated.Still,profitabilityremainsbelowprepandemiclevels.Therecoverywillbeuneven.EBITDAwillfacerenewedpressurethrough2027asACAsubsidyexpirationandMedicaiddisenrollmentincreasethenumberofthosewithoutinsuranceandtherateofuncompensatedcare,withadditional

downsidefrompotentialMedicaidreimbursementchangesandsite-neutralitypolicies.

Beyond2027,marginsshouldgraduallyimproveascommercialenrollmentrecovers,annualrateincreasesflowthrough,andproviderscapturefurtheroperatingefficiencies.ButreductionsinMedicaidstate-

directedpaymentscouldtempertherecovery.ProviderEBITDAcontinuestoshifttowardlower-cost

ambulatoryandhome-basedsettings.ASCsaregaininghigher-acuityproceduresaspayerssteercare

towardlower-costsitesandastheCentersforMedicare&MedicaidServices(CMS)expandstheASC

CoveredProceduresList,broadeningtherangeofprocedureseligibletomigratefromhospitalsettings.Inpostacutesettings,homehealth,hospice,andassistedlivingfacilities(ALFs)areexpectedtoseeincreaseddemandfromagingdemographicsandpatientpreferenceforhome-basedcare.Withinphysicianpractices,specialtyandancillary-rich(forexample,labandimagingservices)modelsareemergingasgrowthengines,whiletraditionalprimarycareremainsrelativelylower-margin.Together,theseshiftsarereducingthe

relativecontributionoftraditionalacuteandinstitutionalsettingstooverallproviderEBITDA.

BudgetOffice,June15,2026.

8CBOBlog,"AcallfornewresearchontheNoSurprisesAct"blogentrybyJessicaHale,TamaraHayford,andDariaPelech,Congressional

WhattoexpectinUShealthcarein2027andbeyond5

Healthcareservicesandtechnology

HSTisexpectedtoremainthefastest-growingsubsectorinhealthcare.Weestimatethatrevenuewillgrow7to8percentandEBITDA9to10percentannually,increasingrevenuepoolstomorethan$500billion

andEBITDApoolstomorethan$120billionby2030.Underlyingthatgrowthisashiftinmixfromlegacy

outsourcedservicestowarddataandanalytics,softwareplatforms,andtechnology-enabledservices.

TherapidemergenceofAlisacceleratingthisbroadertrendandisexpectedtoincreasethevariabilityof

revenueandEBITDAgrowthoutcomesforHSTcompanies.HSTplayersfacearisingdisplacementriskif

theydonotadoptAlatscale;ontheotherhand,therearemarginexpansionopportunitiesforthosethatdo.9

Healthcarehashistoricallystruggledtoconverttechnologyintoproductivity,withoutputperemployeeinhealthcaredeliveryessentiallyflatoverthepast25yearswhileotherservicesindustriesadvancedmorethan50percentoverthesameperiod.0EarlysignssuggestAlmaybreakthatpatternbecauseadoptionhasmovedwellbeyondexperimentationacrossmanyhealthcareorganizationsandagrowingshareof

implementersarebeginningtoshowmeasurablepositivereturns.MostconsequentiallyforHST,morethanthree-quartersofhealthcareorganizationssaytheyintendtopartnerorbuyratherthanbuildthecapabilitiesneededtocapturevaluefromAI."Thiscouldcreatesubstantialdemandforvendorsabletosupplyscarcetalent,infrastructure,changemanagement,andexecutionatpace.

CompetitionintheHSTsegmentisevolvingasnewAl-nativechallengersemergewhobringspeed,

focus,andlower-costdeliverymodels.Atthesametime,incumbentHSTplayerswhohavedurabledata

andworkflowadvantagesarestartingtoreimaginethoseworkflowsinanAlworld,potentiallyleadingto

greateroperationalefficienciesandcostsavings.Thecombinationofmorecompetitionandincumbents'

advantagesiscontributingtoacceleratedoutsourcingasprovidersandpayerslooktoHSTvendorsasawaytoaugmenttheirownworkflowsandbenefitfromthecostsavingspotentialofAI.AscompetitionbetweentheseHSTincumbentsandinnovatorsincreases,legacyservices-basedsegmentswithinHST,suchascoreadministrativeservices,mayseepricepressureoverthenextthreetofiveyearsasvendorscompetetoearnshare.

Pharmacyservices

Pharmacyremainsoneofhealthcare'sfastest-growingsegments.Weestimatepharmacyvaluechain

EBITDAwillgrowfrom$97billionin2025to$138billionby2030,roughly7percentannually,withspecialtypharmacyandinfusionservicesaccountingfornearlyhalfofthe2030pool.Hospital-ownedspecialty

pharmacyisthefastest-growingsegment,expandingabout15percentannually,whilephysicianofficeandhomeinfusionarecapturinganincreasingshareofcareastreatmentshiftsacrosssites.

Awaveofregulatoryaction-includingpharmacybenefitmanager(PBM)transparencyprovisions(for

example,theConsolidatedAppropriationsAct,2026),Medicaredrugpricenegotiations,MostFavored

Nation(MFN)pricing,arevised340BDrugPricingProgramrebatepilot,andsite-neutralpayment

reforms-isreshapingeconomicsacrossthepharmacyvaluechain.Meanwhile,PBMreformsareincreasingpressureontraditionalrebate-andspread-basedmarginsandareacceleratingashifttowardfee-based

compensationmodels.

Theresultisasectorinwhichaggregategrowthremainsresilientbutinwhichvalueisbeingredistributedacrossstakeholdersandsitesofcare.Competitiveadvantagewillincreasinglydependontheabilityto

manageclinicaloutcomes,adaptcontractingmodels,anddemonstratedifferentiatedcapabilitiesbeyondtraditionalformularyandutilization-managementlevers.

Let'slookmorecloselyatsubsectorperformance.

9HSTprojectionsincorporatetheexpectedimpactofAl.ProjectionsforothersegmentsdonotyetexplicitlyeflectAl-drivenproductivityormargineffectsandwillbeupdatedinafutureedition.

10McKinseyanalysisofthepercentchangeinrealgrossoutputperful-time-equivalentemployee,1998-2023,chained(2017)dolaseries,fromtheUSBureauofEconomicAnalysis.

WhattoexpectinUShealthcarein2027andbeyond6

Payers:Pricingbeginstocatchuptomedical-costtrendsafterahistoricmarginsqueeze,settingupanunevenrecovery

TotalEBITDAdeclinedfrom$32billionin2024toabout$9billionin2025.Acrossthemajorpayersegments(group,individual,andgovernment),EBITDAfellfromabout$51billionin2023and$20billionin2024to

roughly-$4billionin2025.Thisisthefirsttimethisdecadethatthebusinessofbearingmedicalriskhas

collectivelygeneratednegativeEBITDA.However,thedeclineinthepayermarkethasbeenuneven,markedbygrowingdivergenceacrosssegmentsbasedonsizeandtypeofcarrier.

Thesharpdeteriorationreflectselevatedmedical-costinflationflowingthroughpayerclaimsfasterthan

premiumpricingandgovernmentratescanadjust.Highermedicalutilization,risingproviderunitcosts,

increasedGLP-1andspecialtypharmacyutilization,andbehavioralhealthdemandaccountedforthegap

betweenpremiumgrowthandclaimscosts,leadingtomargincompressionacrossrisk-bearingbusinesses.Coverageshiftscompoundedthepressure.Medicaidredeterminationleftasmaller,higher-acuityretainedpopulation,whilemembersmovingfromMedicaidintotheACAexchangesincreasedriskpoolmorbidityandcontributedtothesharpdeteriorationinindividual-marketeconomics.

Performancealsodivergedsharplybypayerscaleandbusinessmixin2025:Small-sizepayers(thosewith

lessthan100,000members)have5percentlessaverageEBITDAmarginthanlarge-sizepayers(thosewithmorethan500,000).Diversifiednationalpayersremainedprofitableintheircorepayerbusinessesin2025,whilenationalswithnarrowportfoliosgeneratedonlymodestearnings;otherpayerscollectivelyrecordedlosses(Exhibit2).Inadditiontoperformingbetterinthecorepayerbusiness,diversifiednationalsalsohavelowerexposuretothecorepayerbusinessoverall(Exhibit3).Together,theseresultspointtotherecent

advantagesofscaleandadiversifiedearningsbaseinnavigatingperiodsofelevatedpressureonmedicalcosts.

Exhibit2

Payerprofitabilityhasdivergedsharply,withdiversifiednationalscapturingthemajorityofcorepayerearnings.

CorepayerbusinessEBITDAbypayertype,2025,$billion

Diversifiednationals²

Narrowportfolionationals³1.2

Allotherpayers-12.2

PayersegmentEBITDAforeachpayerisestimatedbasedonreportedoperatingmarginandD8AexpensesFiguresexcludestop-los,indvidualcoveragehealthreimbursementarrangements,thefixed-benefitandsupplementalsegment,andancillarysegments.

²UnitedHealthGroup,Elevance,Cigna,andAetna.

Centene,Humana,andMolina.

Source:NationalAssociationofInsuranceCommissionersfilings;McKinseyValuePoolsModel

McKinsey&Company

"McKinseyQ22026USGenAIHealthcareSurvey,July2026,n=120(40payers,40providers,and40HSTplayers).

Exhibit3

Nationalplayershavediversifiedearnings,withlower-marginpayer

businessescontributingabout20to60percentofoperatingincome.

Shareofoperatingincomefrompayerlines,2025,%

Elevance

UnitedHealthGroup

Cigna

Aetna20

McKinsey&Company

Entering2026,payerpricingbegantocatchupwithelevatedmedical-costtrends,animportantinflectionpointafterseveralyearsinwhichclaimsgrowthoutpacedrateactions.Early2026payerresultsconfirmthatpricingandbenefitactionsaretranslatingintomedical-costperformanceimprovements.CommercialandACAcarriersincreasedpremiumssubstantially,whileimprovedMAfundingandcontinuedproduct

andbenefitoptimizationprovidedadditionalsupport.However,EBITDAresultsareexpectedtolagbehindbecausehigherrateswillbeoffsetbybuy-downsandenrollmentandriskpoolpressurespersist.More

meaningfulEBITDArecoveryisexpectedtoemergefrom2028onward.

Theoutlookalsovariessubstantiallybysegment(Exhibit4).Commercialfullyinsuredgroupsegment

andMAsegmentmarginsareexpectedtoimprovegraduallythrough2030butarelikelytoremainbelow

historicallevelsamidpersistentpressureonmedicalcostsandslowingmembership.Theindividualand

MedicaidsegmentsfacethesharpestenrollmentresetsfromACAsubsidyexpirationandMedicaideligibilitychanges.Theirrecoverypathsalsodiverge:TheACAsegmentislikelytomaintainmodestlypositivemarginsthroughaggressiverepricing,whileMedicaidrecoveryislikelytoremainslowergivenrate-settinglagsandfurthereligibility-relatedpressurein2027-28.

WhattoexpectinUShealthcarein2027andbeyond7

WhattoexpectinUShealthcarein2027andbeyond8

Exhibit4

By2030,mostlinesofpayerbusinessesareexpectedtorecoverfrom2025lows,thoughmarginsmaystaybelowprepandemiclevels.

DistributionofprojectedhealthcareEBITDAacrosspayersegments,2030,$billion

Hospitalindemnity

-

Long-

2025-30CAGR,%<00-<55-10>10

Largegroup

IQRA°

Duaks

Dental

Accident

and

AD&D

Indviduad

Stup-loss

Short-

term

disability

Vision

Medicaid

Admristraltiveservicesory

Critical

illness

MAandMAPD⁵

Long-

term

disability

Thind-partyadministralor

Prescipiondug

Smallgroup

Medicaresupplement

termcare

Group

Individual

Government

Ancillary

28

8

33

8Fixed-

benefitandsupplemental

2

IExcludesivestmentincome.Excludethird-partyadministrator.Ilndividualcoveragehealthreimbursementarangement.ExcludesICHRA5MedicareAdvan-tageandMedicareAdvantagePrescriptionDrug.5Accidentaldeathanddismemberment.

Source:McKinseyValuePoolsModel

McKinsey&Company

Groupinsurance

Groupinsuranceisakeydriverofthepayerrecovery.EBITDAfelltoabout$3billionin2025,butitis

expectedtoreboundtoabout$28billionby2030(aboutone-thirdofpayerEBITDA)assustainedrate

actionsbegintocatchupwithelevatedmedical-costtrendsandimproveunderwritingperformance.Fullyinsuredmarginsshouldrecovergraduallyaspremiumgrowthoutpacesclaimsgrowth.Butpersistent

WhattoexpectinUShealthcarein2027andbeyond9

utilizationandunitcostpressuresaswellascontinuedmigrationtowardalternativefundingarrangements,suchaslevel-fundedinsurance,arelikelytokeepprofitabilitybelowhistoricallevels.

Withinfullyinsuredlargeandsmallgroupsegments,revenuepermemberperyear(PMPY)isexpectedto

rise9to12percentin2026beforenormalizingto5to8percentoverthelongertermaspayerspushthroughrateincreasestocatchupwithelevatedmedicalcosts.Evenwiththesepricingactions,returningfullyinsuredmarginstothehistorical3to4percentrangewillremainchallenging.Inthesmallgroupsegment,acceleratingcoveragedeclinesandthemigrationofhealthieremployerstowardalternativefundingarrangementscouldleaveasmaller,higher-acuityfullyinsuredpool,sustainingupwardpressureonclaimstrends.

Thelargegroupsegmentfacesasimilarstructuralshiftasemployersincreasinglymovetowardself-insuredandotheralternative-fundedproducts,reducingthefullyinsuredriskpool.Together,theseshiftsincreaserelianceonsustainedpricingdisciplineaswellasmoderationinutilizationandunitcosttrendstorestore

historicalprofitability.Scaleprovidessomeprotectionbecauselargercarriersarebetterpositionedtoabsorbunderwritingvolatilityandspreadadministrativecosts,whilesmallercarriersfaceamoredifficultpathbacktoprofitability.

Self-insuredmembership

Self-insuredmembershipisexpectedtoincreaseabout1.0to1.5percentannually,withstrongergrowthfrom2027onwardasemployerscontinueshiftingfromfullyinsuredtoself-fundedmodelsandassomemembersdisenrolledfromMedicaidandtheACAmoveintoemployercoverage.Marginsarelikelytoholdsteadyat8to9percent,supportedbyattractiveeconomicsacrossASOadministrationandadjacentofferingssuchasstop-lossmodels.Withinthissegment,third-party-administratorenrollment,whichcurrentlyrepresentsabout26

percentoftotalASOmembership,isexpectedtoriseto30percentby2030,withrevenuePMPYgrowing1to2percentandEBITDArising6to7percentannuallyoverthe2025-30period.

ACAmarket

ACAmarginsdeclinedsharplyto-3.7percentin2025,promptingpayerstosecureapprovedpremium

increasesofabout26percentfor2026toaddresselevatedmedical-costtrendsandrestoreprofitability.However,theexpirationofenhancedsubsidiesintroducesanewheadwind:Enrollmenthasalreadydeclinedbyapproximately5.0millionpeoplein2026,withafurther3.5millionto4.0milliondropanticipatedin

2027.1²Ashealthierandmore-price-sensitivemembersdisproportionatelyexit,theremainingriskpool

islikelytobecomehigheracuity,requiringcontinuedrepricing.Afurther11percentpremiumincreaseis

projectedfor2027,helpingmarginsreturntoandremainmodestlypositivedespiteamateriallysmallerandhigher-costmembershipbase.

TheseactionsmakeACAoneoftheclearestexamplesofpayersproactivelyrepricingforanticipated

deterioration,reflectingbothunderlyingmedical-costtrendsandworseningriskpoolmorbidityfollowingsubsidyexpiration.Buy-downsareexpectedtooffsetaboutthreetofourpercentagepointsofpremiumgrowth,moderatingrealizedrevenuePMPYgrowth.Despitetheenrollmentreset,marginsarelikelyto

remainpositiveatroughly2to3percent,withrevenuePMPYgrowthnormalizingto4to5percentoverthelongerterm.

MedicareAdvantage

TheMAsegmententered2025understress.Marginswerepressuredin2024,approachingbreakeven

overall,andslippedintooutrightlossesin2025.EBITDAisexpectedtorecoverfromroughly-$3.4billionin2025toabout$11billionby2030,stabilizingneara2percentlong-termtarget-thoughstillbelowhistoricallevels.Theturnhingesonpolicyandpricing:CMS'sestimatedaverageMApaymentupdateincreasedfrom3.70percentin2025to5.06percentin20263;2026isthefinalyearoftheCMS-HCCVersion28risk

adjustmentmodelphase-in;andtheInflationReductionAct'sPartDredesigncontinuestoweighonPartDstand-aloneandMAprescriptiondrugplaneconomics.

12"Theaveragemarketplacedeductiblegrewbyabout$1,000perpersonin2026,withmoreenrollesshiftingtohigher-deductibleplansasenhancedtaxcreditsexpired,"KFF,May19,2026.

3“2025MedicareAdvantageandPartDrateannouncement,"CMS.gov,April1,2024;“2026MedicareAdvantageandPartDrateannouncement,"CMS.gov,April7,2025.

Persistentfundingandutilizationpressuresaredrivingpayerstowardpricingactions,benefitredesign,productoptimization,andmoreselectivemarketparticipation,supportingmarginrecoverywhile

moderatingenrollmentgrowth.Scaleremainsanadvantage,withlargerMAcarriersbetterpositionedtoabsorbvolatilityandoptimizeproductsacrossmarkets.

Overthelongerterm,utilizationstabilization,improvedfunding,andcontinuedproductoptimizationshouldsupport100to250basispointsofmarginimprovementfromdepressed2025levels,bringingmarginstoroughly2percentby2030.MApenetrationisexpectedtostabilizeat50to55percentoftotalMedicarebeneficiaries,withmembershipgrowthfallingfrom7percentannuallyinthe2019-25periodtoabout3

to4percentannuallygoingforward,accordingtoCongressionalBudgetOfficeestimates.CMSpaymentupdates,alongwithcontinuedriskscoregrowth,shouldsupportnear-termMArevenuegrowth,with

revenuePMPYprojectedtogrowabout7percentin2026beforefallingto4to5percentannuallyasthesefactorsnormalize.

Medicaid

Medicaidenrollmentdeclinedbytwomilliontothreemillionmembersin2024-25aspublichealth

emergencymeasurescontinuedtounwind,accor

温馨提示

  • 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
  • 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
  • 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
  • 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
  • 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
  • 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
  • 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。

评论

0/150

提交评论